Keyphrases
Acute Lymphoblastic Leukemia
100%
Blinatumomab
100%
Relapsed or Refractory
100%
T Cells
40%
CD19
40%
Clinical Trials
20%
B Cells
20%
Leukemia
20%
U.S. Food
20%
Monoclonal Antibody
20%
Neoplastic Disease
20%
Minimal Residual Disease
20%
BCP-ALL
20%
Philadelphia Chromosome-negative
20%
Lysis
20%
Lymphoma
20%
Cytotoxic T Cells
20%
Perforin
20%
CD19+
20%
Non-Hodgkin Lymphoma
20%
Review Process
20%
Mature B Cells
20%
CD3 Bispecific
20%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
100%
Blinatumomab
100%
B Cell
60%
T Cell
40%
Neoplasm
20%
Precursor
20%
Philadelphia 1 Chromosome
20%
Minimal Residual Disease
20%
Perforin
20%
Non-Hodgkin Lymphoma
20%
CD3 Antigen
20%
Cytotoxic T-Cell
20%
Clinical Trial
20%
Leukemia
20%
Monoclonal Antibody
20%
Immunotherapy
20%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
100%
Blinatumomab
100%
Leukemia
20%
Clinical Trial
20%
Neoplasm
20%
Monoclonal Antibody
20%
Immunotherapy
20%
Minimal Residual Disease
20%
Perforin
20%
Nonhodgkin Lymphoma
20%
Philadelphia 1 Chromosome
20%
CD3 Antigen
20%
Immunology and Microbiology
Blinatumomab
100%
B Cell
60%
CD19
60%
T Cell
40%
Cytotoxic T Cell
20%
Precursor
20%
Immunotherapy
20%
Monoclonal Antibody
20%
Perforin
20%
Philadelphia 1 Chromosome
20%
CD3 Antigen
20%